- Login
- Register
- Home/Current Issue
- About the journal
- Editorial board
- Online submission
- Instructions for authors
- Subscriptions
- Foundation Acta Endocrinologica
- Archive
- Contact
Romanian Academy
The Publishing House of the Romanian Academy
ACTA ENDOCRINOLOGICA (BUC)
The International Journal of Romanian Society of Endocrinology / Registered in 1938in Web of Science Master Journal List
Acta Endocrinologica(Bucharest) is live in PubMed Central
Journal Impact Factor - click here.
-
Clinical review/Extensive clinical experience
Pezzani R
Adrenocortical Carcinoma: in the Search for a Pre-Operative BiomarkerActa Endo (Buc) 2017 13(3): 340-341 doi: 10.4183/aeb.2017.340
AbstractAdrenocortical tumors (ACT) are common malignancies of the cortex adrenal gland frequently non-functioning and benign. Differently, adrenocortical carcinoma (ACC) is a very rare neoplasia with an incidence of 0.7–2.0 cases per million people and an aggressive behaviour. Moreover ACC shows a poor prognosis with an estimated survival of 16-38%. Only surgery and the use of mitotane (sometime associated to standard chemotherapy) can represent a useful tool to fight against this malignancy, nonetheless ACC often metastasizes and recurs, decreasing considerably patient survival prospect. In the search of new potential tools to combat cancer, in the latest years omics works extended our knowledge on the ACC pathogenesis and made possible the investigation of novel ACC biomarkers. In this field of research, epigenetic studies identified a common signature in ACC, where the most altered miRNA found in ACC (miR-483-5p) seems now to represent a concrete biomarker to be used in the pre-operative diagnosis of ACC. A larger patient cohort is necessary to confirm this pivotal data: collaboration between scientific communities will be the key to determine the success of this fundamental discovery. -
Perspectives
Badiu C
Cardio-Endocrinology Different Approaches, Common TargetsActa Endo (Buc) 2012 8(3): 341-343 doi: 10.4183/aeb.2012.341
Abstract- -
Editorial
Grigorescu F
Insulin resistance: from naive understanding of genetics to the complexity of endocrine and metabolic diseasesActa Endo (Buc) 2005 1(3): 341-350 doi: 10.4183/aeb.2005.341
-
Endocrine Care
Hartavi M, Kizilgul M, Koca FI, Takir M
Effect of Orlistat or Orlistat Plus Metformin Treatment in Patients with Morbid Obesity: A Single-Center ExperienceActa Endo (Buc) 2024 20(3): 341-348 doi: 10.4183/aeb.2024.341
AbstractBackground. Up to this point, individual or population-based approaches for treating and preventing obesity have not yielded lasting success. We assessed the impact of orlistat with or without metformin on anthropometric and laboratory measurements as well as cardiovascular risk factors in patients suffering from severe obesity. Methods. A total of 116 patients with morbid obesity, consisting of 105 females and 11 males, were involved in the study. Of these, 30 patients (29 females and 1 male) underwent treatment with orlistat, while 86 patients (70 females and 10 males) were given a combination of orlistat and metformin. The effects of orlistat treatment, either 360 mg/day alone or orlistat plus metformin at a dose of 1700 mg/day, were retrospectively examined in patients who had been compliant with therapy for at least three months and had also made adjustments to their diet and lifestyle. Results. The mean age in the orlistat group was 46.26 ± 11.30 years, and 43.13 ± 11.37 years in the orlistat plus metformin group. Significant reductions in weight, body mass index (BMI), waist circumference (WC), systolic blood pressure (BP), total cholesterol, LDL-cholesterol, and carotid intima media thickness (CIMT) resulted from three months of orlistat treatment (p < 0.01). The combination of orlistat and metformin produced substantial reductions in weight, BMI, WC, systolic BP, diastolic BP, CIMT, fasting blood glucose, total cholesterol levels, homeostatic model assessment for insulin resistance (HOMA-IR), and HbA1c levels (p < 0.01). The groups showed comparable weight, BMI, and WC. Neither group experienced notable side effects. Conclusions. Treatments with orlistat and orlistat in combination with metformin led to a significant reduction in body weight. Similar body weight changes were observed between the groups, whereas the alterations in fasting plasma glucose, HOMA-IR, and HbA1c levels were greater with orlistat combined with metformin treatment. -
Case Report
Cansu GB, Taskiran B, Bahçeci T
Thyroid Hemiagenesis Associated with Graves' Disease: A Case Report and Review of the LiteratureActa Endo (Buc) 2017 13(3): 342-348 doi: 10.4183/aeb.2017.342
AbstractIntroduction. Thyroid hemiagenesis (TH) is a congenital developmental disorder. Most cases are euthyroid although hyperthyroidism, hypothyroidism, and malignancy may develop. We present a case of hemiagenesis with Graves’ disease (GD) and review the literature about the association. Case report. A 45-year-old female patient was admitted to the endocrinology department due to nausea and diarrhea. Her past medical history revealed hyperthyroidism diagnosed a year ago. On thyroid examination, right thyroid lobe was palpable, but left lobe and isthmus were not. Physical examination involving other organ systems was unremarkable except for fine tremor of the hands. Thyroid function tests revealed a high level of free T4 and T3 with a low serum TSH. Thyroid antibodies were all positive. Left lobe and isthmus were invisible on thyroid ultrasonography (US) and the right thyroid lobe measuring 44x18x12 mm was diffusely heterogeneous in echo texture. Thyroid scan using Technetium-99m showed increased homogeneous tracer uptake in the right lobe. The patient was diagnosed with TH and GD. Discussion. In case of unilateral increased uptake on scintiscan, GD with hemiagenesis must be kept in mind in the differential diagnosis of autonomous solitary adenoma, postinflammatory atrophy of thyroid in Hashimoto’s disease, focal or unilateral subacute thyroiditis, and primary or metastatic carcinoma. It is prudent to do thyroid ultrasound along with scintigram. US is a valuable tool for the quick diagnosis of TH and differential diagnosis from other causes. -
Endocrine Care
Dehelean L, Romosan AM, Manea MM, Papava I, Andor M, Romosan RS
The Metabolic Syndrome in Outpatients with Psychosis: a Comparative Study Between Long Acting Injectable Olanzapine and RisperidoneActa Endo (Buc) 2019 15(3): 342-348 doi: 10.4183/aeb.2019.342
AbstractContext. Literature shows that patients taking antipsychotic medication risk developing metabolic complications. Objective. The study aims to compare the presence of the metabolic syndrome (MS) and its components in outpatients treated with long acting injectable (LAI) olanzapine and risperidone. Design. A double-center study was performed on outpatients with psychosis, which were divided into two samples: one treated with olanzapine and another with risperidone. Subjects and Methods. The following data were analyzed: age, gender, severity of psychiatric symptoms, blood pressure, waist circumference, fasting blood glucose, lipid profile, tobacco use, medication, and time intervals related to psychosis duration (pre-LAI and LAI treatment). Results. The study included 77 patients with schizophrenia and schizoaffective disorder. MS was present in 45 (58.4%) patients. Subjects with MS and abdominal obesity had higher durations of psychosis and of LAI treatment. Patients with hypertension had a higher pre- LAI treatment interval. Risperidone was associated with higher rates of hypertension and higher values of abdominal circumference than olanzapine. Conclusions. The presence of MS is related to the duration of the psychosis and the time spent on LAI treatment with no differences between olanzapine and risperidone. Hypertension may be a consequence of age, disorder induced stress, or of treatment with risperidone. -
Endocrine Care
Deacu LG, Niculescu DA, Terzea D, Cristea C, Ioachim D, Poiana C
The Learning Curve and Performance of a Newly Established Thyroid Fineneedle Aspiration CenterActa Endo (Buc) 2022 18(3): 343-349 doi: 10.4183/aeb.2022.343
AbstractContext. Thyroid fine-needle aspiration (FNA) cytology is the best tool for preoperative diagnosis of thyroid carcinoma; however, its learning curve is poorly described. Our aim was to assess the learning curve of a new thyroid FNA center involving unexperienced operator and pathologist. Methods. We retrieved from our tertiary endocrinology center database all thyroid FNA procedures done by a single operator (endocrinologist with no experience in FNA) between 2018 and 2021. Cytology was assessed by two pathologists with limited or no experience in thyroid cytology. We also got the corresponding sex, age, nodule diameter, EU-TIRADS score, Bethesda category and final pathology report. Results. There were 1872 FNA in 1618 patients. Proportion of Bethesda 1 nodules decreased significantly (p for trend=0.003) from 17% in the first 100 FNA procedures to 4% in the 401-500 group of procedures, and remained constant between 9% and 4% (p for trend=NS) for the rest of the study. Proportion of Bethesda 2 rose steady from 26% in the first 100 nodules to 80.1% in the last 241 nodules (p for trend<0.001). Indeterminate lesions (Bethesda 3 and 4) decreased significantly (p for trend=0.001) from 16% and 35% in the first 100 nodules to 2.5% and 5.8% in the last 241 lesions. Proportions of Bethesda 5+6 categories varied non-significantly over time. There were no time trends in the malignancy rate of surgically removed nodules. Conclusions. At least 300 procedures are needed to reach the standard performance. A steadily state for the whole center is obtained after about 500 procedures. -
Endocrine Care
Valean C, Ichim G, Tatar S, Samasca G, Leucuta A, Nanulescu MV
Prevalence of metabolic syndrome and serum profile of adipokines (leptin and adiponectin) in children with overweight or obesityActa Endo (Buc) 2010 6(3): 343-354 doi: 10.4183/aeb.2010.343
AbstractBackground. Metabolic syndrome is an important risk factor for cardiovascular diseases. \r\nObjective. Evaluating the prevalence of metabolic syndrome and serum profile of adipokines in children with overweight or obesity. \r\nMethods. Sixty two children were included in the study, with a body mass index (BMI) that exceeded 85th percentile. Waist circumference and blood pressure (BP) were recorded, followed by the determination of: glucose, cholesterol, triglycerides, HDL cholesterol, insulin, adiponectin and leptin. The insulin resistance was then calculated. \r\nResults. Of the 52 children included, 28,8% have met the criteria for diagnosis of metabolic syndrome. BMI and BP values were higher in children with metabolic syndrome as well as the values of leptin (69.59 ? 50;89 vs. 58.44 ? 42.28 ng / ml) and insulin resistance (1.65 ? 0 ,74 vs. 1.41? 0.78). We could found a positive correlation, statistically significant between BMI and serum leptin (r = 0.32, p =0.02), BMI and insulin (r = 0.33, p = 0.01) and BMI and insulin resistance (r = 0.33, p = 0.01). \r\nConclusion. Metabolic syndrome has a high prevalence in childhood obesity. The adipokines seem to have a very good correlation with the clinical and bioumoral features of the metabolic syndrome. -
Editorial
Corlan AD
Trends of Romanian Medical Research 1990-2014Acta Endo (Buc) 2015 11(3): 343-347 doi: 10.4183/aeb.2015.343
Abstract- -
Case Report
Stanciu M, Popa FL, Totoian IG, , Bera LG
Orbital Pseudotumor Can Mimic Graves’ OphthalmopathyActa Endo (Buc) 2016 12(3): 344-348 doi: 10.4183/aeb.2016.344
AbstractContext. Orbital pseudotumor (OP) is a benign inflammatory process of the orbit with a large polymorphous lymphoid infiltrate, associated with fibrosis in variable amounts, localized or diffuse. Graves’ ophthalmopathy (GO) is the most common cause of proptosis, unilateral or bilateral. Case report. We report a patient with unilateral proptosis who was initially treated with antithyroid drugs for an euthyroid Graves disease, but the extension of the investigation infirmed this. The MRI findings (inflammation of fat, muscle and the left lacrimal gland) in conjunction with the biopsy infirmed the initial diagnostic and confirmed the OP. Conclusions. Orbital pseudotumor is a rare disorder that can image and clinically mimics some inflammatory disease especialy Graves’ ophthalmopathy. Orbital MRI represents the most important test for diagnostic. A negative TRAb in euthyroid cases of proptosis can be a serious starting point for investigating an OP.